000 01283 a2200361 4500
005 20250514160841.0
264 0 _c20031120
008 200311s 0 0 eng d
022 _a0093-7754
024 7 _a10.1016/s0093-7754(03)00357-9
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLogothetis, Christopher J
245 0 0 _aThe case for a biologically based classification of prostate cancer.
_h[electronic resource]
260 _bSeminars in oncology
_cOct 2003
300 _a562-6 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAndrogen Antagonists
_xtherapeutic use
650 0 4 _aAntineoplastic Agents
_xtherapeutic use
650 0 4 _aCocarcinogenesis
650 0 4 _aCombined Modality Therapy
650 0 4 _aDisease Progression
650 0 4 _aGenetic Predisposition to Disease
_xclassification
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMolecular Biology
_xmethods
650 0 4 _aMutation
_xgenetics
650 0 4 _aPatient Care Team
650 0 4 _aPatient Selection
650 0 4 _aProstatectomy
650 0 4 _aProstatic Neoplasms
_xclassification
773 0 _tSeminars in oncology
_gvol. 30
_gno. 5
_gp. 562-6
856 4 0 _uhttps://doi.org/10.1016/s0093-7754(03)00357-9
_zAvailable from publisher's website
999 _c14313877
_d14313877